Translational and Clinical Research
Mass cytometry and Imaging Mass Cytometry use is expanding in clinical research trials
CyTOF® technology has been adopted for use in dozens of clinical research trials around the world to investigate multiple areas of human disease to understand and improve prevention and therapeutics.
- 50-plus unique markers per panel maximize information from every precious patient sample.
- Cells stained with metal-tagged antibodies can be frozen, stored and shipped reliably.
- Panels are easier to adjust to accommodate new findings than those that are fluorescence-based.
- Multiple publications prove that CyTOF assays and instruments provide reliable and reproducible results.
The use of mass cytometry and Imaging Mass Cytometry™ in clinical trials continues to steadily grow and be standardized across trials related to cancer immunotherapies.
Download the CyTOF clinical trials flyer to learn details about the network involved in standardization of CyTOF in clinical trials and more.
Growing adoption of CyTOF technology in National Clinical Trials
207 Trials as of June 2022
Sources: clinicaltrials.gov and various publications
National Clinical Trials citing CyTOF technology by research area
*Includes allergy, cardiac disease, pulmonary disease and stem cell
The beauty of CyTOF is that you can ask complex questions from one tube of cells or one sample of cells. From one patient sample, we can look at leukemia cells, the T cell compartment, other surrounding cell types and how these cells interact. ”
– Kara Davis, DO | Assistant Professor of Pediatrics, Pediatric Oncologist, Stanford University, Stanford Children’s Health
Cutting Edge Cytometry and Clinical Trials: A Case Study
Caroline Roe, MLI
Cancer & Immunology Core
Method validation studies using the Maxpar® Direct™ Immune Profiling Assay™
Sasidhar Vemula, PhD
Translational Biomarker Solutions
Labcorp Drug Development
CyTOF in the Cancer Immune Monitoring and Analysis Centers (CIMAC): standardization and harmonization
Holden Maecker, PhD
Professor of Microbiology and Immunology
Director of the Human Immune Monitoring Center, Stanford University
A complete immune monitoring solution with CyTOF: Ideal for pandemics and beyond
Frederik De Smet, MSc, PhD
University of Leuven, Belgium
Leveraging CyTOF to track cancer vaccine induced T cell responses for up to 20 years
Erika J. Crosby, PhD
Center for Applied Therapeutics RCR/R&R Curriculum Manager, Duke University Medical Center
Using mass cytometry to identify clinically relevant biological signatures in human health and disease
Brice Gaudilliere, MD, PhD
Associate Professor, Departments of Anesthesiology, Perioperative & Pain Medicine and (by courtesy) of Pediatrics, Stanford University School of Medicine